-
01:59:52 AM

AIM Stock News

01/09/23 8:05 AM
AMEX : AIM
covid-19
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the
RHEA-AI
neutral
11/14/22 7:00 AM
AMEX : AIM
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to
RHEA-AI
neutral
11/03/22 12:34 PM
AMEX : AIM
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
AIM ImmunoTech Inc. today announced that shareholders have re-elected all three of the Company’ s directors, Stewart L. Appelrouth, Thomas K. Equels and William M. Mitchell, at the Company’ s Annual Meeting of Shareholders held today. The Company will file the final voting results on a Form 8- K with the Securities and Exchange Commission. AIM ImmunoTech Inc. is an...
RHEA-AI
neutral